## Correlations between kidney and heart function bioindicators and the expressions of Toll-Like, ACE2, and NRP-1 receptors in COVID-19

- 3
- Rabab Hussain Sultan<sup>1\*</sup>, Maged Abdallah<sup>2</sup>, Tarek Mohamed Ali<sup>3</sup>, Hebatallah Hany
   Assal<sup>4</sup>, Amr E. Ahmed<sup>1</sup>, Basem H Elesawy<sup>5</sup>, and Osama M. Ahmed<sup>6</sup>
- 6
- 1 Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for
   Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt.
- 9 2 Department of anesthesia and intensive care, Kasr Alaini hospital, Cairo University,
  10 Egypt.
- 11 3 Department of Physiology, College of Medicine, Taif University, P.O. Box 11099,
- 12 Taif 21944, Saudi Arabia.
- 13 4 Chest Department, Kasr Alaini hospital, Cairo University, Egypt.
- 5 Department of Pathology, College of Medicine, Taif University, P.O. Box 11099, Taif
   21944, Saudi Arabia.
- 16 6 Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef
- 17 University, P.O. Box 62521, Beni-Suef, Egypt.
- 18
- 19 Corresponding author: Rabab Hussain Sultan, 00201029819222, E-mail:
- 20 <u>rababsoltan080@gmail.com</u>
- 21
  - .
- 22
- 23
- 24
- 25
- 25
- 26
- 27
- 28
- \_\_\_

## 29 Abstract

**Background:** COVID-19 impacts the cardiovascular system resulting in myocardial damage and also affects the kidneys leading to renal dysfunction. This effect is mostly through the binding with angiotensin-converting enzyme-2 (ACE2) and Neuropilin-1(NRP-I) receptors. Toll-Like Receptors (TLRs) typically combine with microbial pathogens and provoke an inflammatory response.

**Aim:** This work aims to compare the changes in kidney and heart function bioindicators 35 and expressions of TLRs (TLR2 and TLR2) as well as ACE2 and NRP-1 receptors in 36 moderate and severe COVID-19 patients. The correlations between kidney and heart 37 function bioindicators and expressions of these receptors are also studied. 38 Patients and Methods: In this study, 50 healthy control and 100 COVID-19 patients (55 39 male and 45 female) were enrolled. According to WHO guidelines, these participants 40 were divided into severe (50 cases) and moderate (50 cases). Serum creatinine, blood 41 urea, CKMB, LDH, and Troponin I were estimated. We measured the gene expression 42 for Toll-Like Receptors (TLR2, TLR4), ACE2, and NRP-1 in the blood samples using 43 quantitative real-time PCR (qRT -PCR). 44

- **Results:** In comparison with the healthy group, all patients exhibited a significant elevation in the serum creatinine, blood urea, cardiac enzymes, and CRP. As well, all studied patients revealed a significant elevation in the expression levels of TLR2, TLR4, ACE2, and NRP-1 mRNA. In all patients, CKMB, ACE2, and NRP-1 mRNA expression levels were positively correlated to both TLR2 and TLR4 expression levels. Moreover, serum creatinine and blood urea were positively correlated to both TLR2 and TLR 4 expression levels in the severe group only.
- 52 **Conclusions**: Our study concluded that expression levels for TLR2, TLR4, ACE2, and 53 NRP-1 mRNA in both severe and moderate patients were positively correlated with 54 renal biomarkers and cardiac enzymes. Innate immune markers can be important 55 because they correlate with the severity of illness in COVID-19.
- 56

57 **Keywords:** Renal function; cardiac enzymes; ACE2; NRP-1; TLRs; COVID-19

- 58
- 59
- 60
- 61
- 62
- 63 Introduction:

64 Coronaviruses are described as a large family of enveloped RNA viruses with a single 65 positive strand. They are capable of infecting humans and many animal species. Based 66 on their pathogenicity, human coronaviruses can be categorized into many types.

67 Highly pathogenic types include severe acute respiratory syndrome coronavirus (SARS-

68 CoV), middle east respiratory syndrome coronavirus (MERS-CoV), and the new severe 69 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Weiss and Navas- Martin,

2005). SARS-CoV-2 has led to the severest pandemic of this century with coronavirus

71 disease 2019 (COVID-19). With the world's second year of the coronavirus pandemic,

governments are still struggling to immunize their populations to the herald immunitylevels.

On November 5, 2021, the total confirmed cases reached about 248,467,363 with 74 5,027,128 deaths due to COVID-19 worldwide (WHO, 2021). Originally recognized as 75 respiratory disease, COVID-19 interacts with the cardiovascular system and causes 76 damage to the heart muscle, and results in cardiac and endothelial dysfunction 77 principally via the angiotensin-converting enzyme 2 (ACE2) receptor (Wang et al., 78 2020). The different tissue tropism between SARS-CoV and SARS-CoV-2 raised the 79 possibility of additional host factors being involved. SARS-CoV-2 advanced protein 80 comprises a cleavage site for protease furin which is not found in SARS-CoV (Peacock 81 et al., 2021). 82

Cantuti-Castelvetri et al. illustrated that neuropilin-1 (NRP-1), which is known to bind 83 furin-cleaved substrates, increases the infectivity of SARS-CoV-2 (Cantuti et al., 2020). 84 Viral invasion actuates the host immune system inducing the creation of a large amount 85 of cytokine and interferons to rule out pathogens. Taking the exception of viral 86 DNA/RNA, the viral proteins are also considered as targets of the model recognition 87 receptor. Membrane-linked receptors like (TLRs 1, 2, 4, 6, and 10) refer to viral protein 88 recognition (Boozari et al., 2019). Distinct Toll-like receivers (TLRs) play a protective 89 and harmful role for a specific virus. The real mechanistic vision of the pathogenicity of 90 SARS-CoV-2 remains uncertain. This is attributable to the lack of knowledge about why 91 the virus chose humans as its primary host and in what way the virus can escape the 92 innate immune system in humans. In particular, the interactions between human TLRs 93 and viral antigens, and the mechanism of cytokine storms that affect several human 94 organs, are not mostly known. Though, the pathophysiology of COVID-19 usually 95 includes the invasion of the virus into the pulmonary alveoli, usually via the respiratory 96 tract, primarily by way of respiratory droplets, through the airways (**Boozari** et al., 97 **2019**). The spike protein, a viral glycoprotein on its capsid, binds to the ACE2 receptor 98

then the RNA genome comes into the host cell through the receptor (Rothan and 99 Byrareddy 2020). After being inside the host cell, viral RNA replicates are formed from 100 mRNA, resulting in quick reproduction of viral RNA and other required structural 101 proteins. Then again, the viral antigens interact with the host's immune cells and this 102 interaction initiates pro-inflammatory reactions like vasodilation, increased capillary 103 permeability, and gathering of humoral factors (V'kovski et al., 2021). All these factors 104 cause the impedance of gas exchange and dyspnea. The exact cause of SARS-CoV-2 and 105 the character of each constituent of the innate and adaptive immune systems are still 106 unidentified (Sette and Crotty 2021). The deficiency of a comprehensive consideration 107 of the pathogenic and immunologic characteristics of the virus made the situation even 108 more alarming to humankind (V'kovski et al., 2021). So, this study aims to evaluate the 109 correlations between mRNA expression levels of Toll-Like Receptors, ACE2 and 110 Neuropilin-1 receptors, and cardiac and renal dysfunction biomarkers in COVID-19. 111

112

## 113 **Patients and Methods**

Study population: We received laboratory-confirmed medical records and edited 114 data of COVID-19 inpatients stated to the National Health Commission in the period 115 from December 2019 to January 2020. The data deadline for the study was March 2021. 116 All the participants were isolated at Misr International Hospital, Cairo, Egypt, in the 117 period from March 2021 to April 2021. Severe COVID-19 patients are defined as those 118 having hypoxemia ( $\leq 93\%$  percutaneous oxygen saturation (SpO2) or  $\geq 30/\text{min}$ 119 respiratory rate on room air who are on the high-flow nasal cannula or noninvasive 120 mechanical ventilation). Patients not fulfilling the above criteria were weighed as 121 moderate. Informed printed consent was taken from all participants after the ethical 122 committee of the institutional review board was permitted this research. 123

Cases of Covid19 were confirmed by the presence of positive results for high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction (RT-PCR) testing of swab samples in the nose and throat (**Raoult** *et al.*, **2020**).

127

Patients: Only cases identified in the laboratory were involved in the study. Eligible
COVID-19 patients aged 20-70 years were divided into 2 groups (50 patients each)
(Chen *et al.*, 2020).

Group1; included patients with moderate symptoms infected by a coronavirus. Group2; included patients with severe symptoms infected by a coronavirus and admitted to the intensive care unit (ICU).

Inclusion and Exclusion Criteria: Healthy individuals were chosen as COVID-19 134 free volunteers. All patients were recruited between 20-70-year-old and were diagnosed 135 as having COVID-19 according to their PCR and chest CT, as identified by WHO 136 2020. Key exclusion criteria included hypertensive patients treated with ACE2 137 inhibitors, pre-existing respiratory disorder, kidney or liver failure, thyroid dysfunction, 138 autoimmune disorders, cerebrovascular diseases, heart diseases, pregnant and lactating 139 women. In addition, patients who receive immunomodulatory drugs or those who have 140 medical conditions such as other infections, malignant tumors, and alcohol abuse. 141

The demographic data: Anthropometric variables such as gender and body mass
 index (BMI) were obtained.

**Blood samples:** Serum samples were rapidly separated, aliquoted, and stored at - 40°C 144 until the biochemical measurements. Serum CK-MB and Troponin I were determined by 145 a standard sandwich enzyme-linked immune-sorbent assay (ELISA) Kit gotten from 146 R&D Systems (USA) as guided by the manufacturer. Gene expression of ACE2 mRNA, 147 NRP-1 mRNA, TLR2, TLR4 were spotted in the healthy control, moderate and severe 148 groups in blood samples (Chen et al., 2020) using quantitative real-time PCR (qRT-149 PCR). Gene sequence (5'-3') procedures were performed conferring to the kit 150 instructions provided in the laboratory assay. 151

#### 152 **Laboratory assays:**

Serum creatinine levels were determined using reagent kits bought from Diamond
Diagnostics (Egypt) conferring to the technique of Henry (1974) (Henry *et al.*, 1974).
Urea concentration was determined according to the technique of Kaplan (1984)
(Kaplan 1984) using a reagent kit purchased from Diamond Diagnostics (Egypt). Serum
lactate dehydrogenase (LDH) activity was measured according to the method of

158 Buhland Jackson (1978) (Buhland and Jackson 1978).

159 **RNA isolation and qRT-PCR:** 

Blood samples of all groups were used separately to extract total RNA via TRIzol

161 Reagent purchased from Fermentas, Germany. Then cDNA synthesis was performed

utilizing the High-Capacity cDNA Reverse Transcription Kit purchased from Invitrogen,

163 Germany according to the manufacturer's directions.

Real-time PCR was carried out in a 20 µL system having 10 µL of 1x Sso- Fast Eva 164 Green Supermix (Bio-Rad, Hercules, CA, USA), 2 µL of cDNA, 6 µL of RNase/DNase-165 free water, and 500nM of the primer pair sequences: NPR1, F:5-AACAACGGCTCGGA 166 CTGGAAGA-3 and R:5-GGTAGATCCTGATGAATCGCGTG -3 (NM001024628); 167 168 ACE2, F: 5-TCCATTGGTCTTCTGTCACCCG-3 and R: 5-AGACCATCCACCTCC ACTTCTC-3 (NM021804.3) β-actin, F: 5-GGAACGGTGAAGGTGACAGCAG-3 and 169 R-5-TGTGGACTTGGGAGAGGACTGG-3 (XM004268956.3); TLR2, F: 5-ATCCTCC 170 AATCAGGCTTCTCT3 and R-5ACACCTCTG TAGGTCACT GTTG3 (NM00131878 171 TLR4. F:5-ATATTGACAGGAAACCCCATCCA-3, **R**: 172 9.2); and 173 AGAGAGATTGAGT AGGGGCATTT-3 (NM138554.5); β– actin. F-5AGGAACGGTGAAGGTGACAGCA G-3 and R-174 5TGTGGACTTGGGAGAGGACTGG-3 (XM00426 8956.3). 175

176 The amplification data were analyzed by using the manufacturer's programmer 177 according to **Livak and Schmittgen** methods (**Livak and Schmittgen 2001**) and the 178 variables were normalized to  $\beta$ -actin.

#### 179 Statistical analysis.

The result values were accessible as mean  $\pm$  standard error. SPSS version 20 for Windows (IBM Corp., 2011) was used for data analysis. The one-way analysis of variance (ANOVA) was used to show the statistical differences among groups. This was followed by Duncan's method for post hoc analysis. By means of the Pearson correlation coefficients method, correlation analysis was estimated between different studied parameters. P-value < 0.05 has been considered as being statistically significant.

#### 186

#### 187 **Results:**

Table 1 shows that the age was significantly higher (p=0.000) in moderate and severe cases compared to healthy controls. Male patients in severe cases were more than female patients. On the other hand, BMI was insignificant (p>0.05) in both infected groups compared to healthy control.

Table 1 shows the levels of the kidney function biomarkers and the cardiac enzymes in all groups. Serum creatinine was significantly higher in severe cases (p=0.000) than in moderate and control cases. No significant difference was found between moderate and control cases. The levels of serum high-sensitivity C-reactive protein (hsCRP) (p=0.000), creatinine kinase MB (CKMB) (p=0.000), lactate dehydrogenase (LDH) (p=0.000), and troponin I (p<0.01) were significantly increased among the severe group

- and moderate group compared to healthy control. Serum (hsCRP) (p=0.000) and levels
- of lactate dehydrogenase (LDH) (p=0.000) were significantly higher among the severe
- 200 group compared to the moderate group.
- 201
- Table (1): Demographic and Laboratory findings of severe and moderate COVID-19.

	Healthy controls	Moderate patients	Severe patients
	(n=50)	(n=50)	(n=50)
Age (Year)	34.12±1.24	58.24±1.24 <sup>****</sup>	57.36±1.43 <sup>****</sup>
Gender, no. (%)			
Male	25(50%)	25(50%)	29 (58%)
Female	25(50%)	25(50%)	21 (42%)
BMI (kg/m <sup>2</sup> )	24.25±0.35	24.73±0.48	25.03±0.52
CRP(mg/dl)	1.97 ±0.19	61.90 ±6.05 + ***	73.92 ±3.42 <sup>****</sup>
Creatinine (mg/dl)	0.89 ±0.03	0.85 ±0.06 <sup>+++</sup>	1.75 ±0. 30**
Urea (mg/dl)	25.1 ±0.93	48.68 ± 5.49 <sup>+++ **</sup>	79.52 ± 9.14 <sup>****</sup>
CKMB (ng/ml)	1.29 ±0.05	4.07 ±0.29 <sup>***</sup>	3.55 ±0.20 <sup>***</sup>
LDH (mg/dl)	261.6±3.00	339.24±25.96 <sup>++ **</sup>	418.7±26.12 <sup>****</sup>
Troponin I (ng/ml)	0.02 ±0.002	0.03 ±0.003	0.04 ±0.01 <sup>****</sup>

Table 1: Data are presented as mean+/-SE. BMI: Body mass index, CRP: C-reactive protein, CKMB: creatinine kinase Myocardial Band, LDH: Lactate dehydrogenase was significantly different at <sup>\*\*</sup> P < 0.01 level, <sup>\*\*\*</sup> P < 0.001 level versus healthy controls, and <sup>+</sup>P < 0.05, <sup>+++</sup>P < 0.001versus severe group.

207

## 208 **Discussion**

The COVID-19 is a global pandemic. From its starting to spread in December 2019, this viral infection continued to spread internationally. So, efforts are instantly done to stop this virus invasion and guard the world.

To progress an effective treatment and vaccine for COVID-19 infection, decoding the precise immune response to this infection is an essential step. In this case, recovery and disease severity were linked to appropriate immune responses and impaired immune reactions, respectively. Our present data has revealed an increase in serum creatinine and blood urea nitrogen (BUN) compared to patients with normal kidney function. In agreement with our results, **Cheng** *et al.* their clinical evidence has shown an elevation in both serum creatinine and BUN in COVID-19 patients, and near 5% of their prospective study in China, patients were diagnosed with acute kidney injury during hospitalization (**Cheng** *et al.*, **2020**).

Ahmadian et al.; Buonaguro et al.; Huang et al. and Wan et al. reported that 221 kidney dysfunction mainly acute kidney injury, occurs in cases with COVID-19 within 3 222 weeks after the beginning of the symptoms; nevertheless, kidney complications are 223 linked to the higher death rate. They concluded that COVID-19 induced organ 224 impairment is mostly facilitated by cytokine storms and that strategies to diminish or 225 eradicate inflammatory cytokines would be effective in avoiding cytokine-induced organ 226 injury. Aiming to the creation of IL1, IL6, TNF, and INF- $\gamma$  related-inhibitors are 227 reported (Ahmadian et al., 2021; Buonaguro et al., 2020; Huang et al., 2020 and Wan 228 et al., 2020). Kidney injury induced by the SARS-CoV-2 virus is probably related to 229 several factors. The virus can infect renal podocytes and cells of the proximal tubules. 230 Disruptive glomerulopathy, leakage of protein in Bowman's capsule, acute tubular 231 necrosis, and mitochondrial damage based on the angiotensin-converting enzyme 2 232 (ACE2) pathway (Fan et al., 2021). 233

- Acute kidney injury can result from dysregulation of the immune response, such as cytokine storms and macrophage activation syndrome with lymphopenia (**Ahmadin** *et al.*, **2021**). The development of cytokine storms after viral infection, directly and indirectly, affects the kidneys and can induce sepsis, shock, hypoxia, and rhabdomyolysis. Among the other probable causes of kidney injury induced by COVID-19 is the organ interactions between the pulmonary, cardiac, and renal tissues (**Qian** *et al.*, **2021**).
- The present study detected a highly significant upsurge of ACE2 mRNA receptor expressions, NRP-1 mRNA co-receptors, in COVID-19patients.

243 This finding was consistent with the results of Imig and Ryan; Cantuti-Castelvetri et

*al.;* Daly *et al.;* Freeman and Swartzand who reported that one of the major receptors

- for SARS-CoV-2 is ACE2 which is broadly dispersed in the lung, intestinal, liver, heart,
   vascular endothelium, testis, and kidney cells.
- The fact that ACE2 is expressed in respiratory and olfactory epithelial cells at very low
- protein levels increases the likelihood that other factors are needed to promote virus-host
- cell communications in the cells that express low ACE2. NRP-1 may be considered as
- an ACE2 enhancer by facilitating the interface of the virus and ACE2. In addition, TLRs
- are associated with acute kidney injury, which correlates with the severity of renal

disease and inflammatory markers (Imig and Ryan 2013; Cantuti-Castelvetri *et al.*,
2020; Daly *et al.*, 2020 and Freeman and Swartz 2020).

Moreover, Rivero et al. and Choudhury and Mukherjee, concluded these TLRs (2) 254 and 4) can encourage the expression of chemokine in epithelial cells of renal tubules 255 256 (Rivero *et al.*, 2009 Choudhury and Mukherjee 2020). Viruses interrelate with precise receptors to enter target cells. SARS-CoV-2 interacts with the angiotensin-converting 257 enzyme 2 receptors (ACE2), which is broadly distributed in the lung, intestinal, liver, 258 heart, vascular endothelium, testis, and kidney cells (Gheblawi et al., 2020). With the 259 help of the type II transmembrane serine protease (TMPRSS2), SARS-CoV-2 comes 260 into the host cells by endocytosis (Hoffman et al., 2020). Zhang et al. revealed that 261 severe COVID-19 patients must show a hyper inflammation nature in comparison to 262 non-severe patients (Zhang et al., 2020). 263

S1 subunit of the S spike of SARS-CoV-2 has a c-terminal domain that guarantees a very high attraction for the ACE2 receptor (**Huang** *et al.*, **2020**). This declines the ACE2 expression on the cell surface and upsurges inflammation leading to tissues destruction (**Li** *et al.*, **2020**). ACE2 plays an anti-inflammatory role by converting angiotensin II into angiotensin (1-7) (**Issa** *et al.*, (**2021**) and reducing vaso-permeability, edema, and

- 269 pulmonary neutrophil infiltration.
- Ziegler *et al.* recommended that SARS-CoV-2 may raise ACE2 expression and further
  increase infection (Ziegler *et al.*, 2020). The spike protein of SARS-CoV-2 comprises a
  cleavage site for the protease furin which is lacking in SARS-CoV. Cantuti Castelvetri *et al.* presented that neuropilin-1 (NRP-1), which is identified to bind to furin-cleaving
  substrates, enhances SARS-CoV-2 infectivity (Cantuti-Castelvetri *et al.*, 2020).
- Daly et al. reported that the furin-cleaving S1 fragment of the spike protein directly 275 combines to cell surface NRP-1 and the blocking of this contact with small molecule 276 inhibitors or monoclonal antibodies, will reduce viral invasion in cell culture (Daly et 277 al., 2020). Viral invasion initiates inflammation, stimulation of specialized antigen-278 presenting cells (APCs) that make the viral peptides presentable to T cells (CD4 and 279 CD8) and stimulates B cells directly. Inflammation is dependent on the first line of 280 innate immune response (Shah et al., 2020). As soon as SARS-CoV-2 enters the host 281 cell, it triggers the pyrin domain containing 3 (NLRP3) inflammasome, one of the Nod-282 like receptor family. Once the viral RNA interacts with TLRs 3, 7, 8, and 9, A 283 downstream of the NF $\square$   $\kappa$ B pathway becomes activated, which augments the production 284 of pro-inflammatory cytokines (Browne 2020). TLR2 and TLR4 are crucial due to their 285 exciting capability to identify different molecular forms of attacking pathogens 286

(Mukherjee et al., 2016). Subsequently, the inflammation twitches and the activated 287 immune cells explode the release of a large number of cytokines. Collectively, these 288 mechanisms participate in augmenting the inflammatory response that plays a major role 289 in the pathogenesis of COVID-19 (Ye et al., 2020). The "cytokine storm syndrome" is 290 believed to be a major underlying factor in the immune-pathogenicity of COVID-19. 291 This storm is responsible for the start of tissue damage, hyper inflammation, and even 292 mortality (Tang et al., 2020). It was activated by the hyperactivation of immune cells 293 leading to a boom of cytokines release. The overexpression of induced IL-10, 294 macrophage IL-1  $\alpha$ , hepatocyte growth factor, IFN- $\Box$ , IL-3, and were highly related to 295 the severity of the disease (Tang et al., 2020). Freeman and Swartz concluded that 296 SARS-CoV-2 is typified by strong and fast stimulation of the innate immune defense, 297 involving triggering of the NLRP3 pathway, and the release of the IL-6 and IL-1 (Daly 298 et al., 2020). Blanco-Melo et al. verified that SARS-CoV-2 infection of the epithelial 299 cells of human bronchi gave rise to the expression of numerous cytokines and 300 chemokines like TNF-α, IL-1β, and IL-6 (Blanco-Melo et al., 2020). In addition, our 301 present data showed an elevated troponin I, lactate dehydrogenase (LDH), and CKMB in 302 moderate and severe COVID-19 patients when compared with the control group. 303 COVID-19 has been shown to interrelate and disturb the cardiovascular system, 304 primarily via the ACE2 receptor, resulting in myocardial damage, cardiac damage, and 305 endothelial dysfunction (Basu-Ray et al., 2020). The interface of SARS-CoV-2 with 306 ACE2 can give rise to changes in the ACE2 pathways, causing acute cardiac injury. A 307 few studies propose that SARS-CoV-2 can result in viral myocarditis by direct infection 308 of the myocardium. In many cases, myocardial damage seems to be triggered by 309 increased cardiac metabolic demand which accompanies systemic infections and 310 persistent severe pneumonia-induced hypoxia (Basu-Ray et al., 2020 and Bugert et al., 311 **2021**). Moreover, the release of high levels of interleukin 2, 10, 6, 8, and TNF- $\alpha$  can 312 harm several tissues, like vascular endothelium and cardiac myocytes (Tang et al., 313 2020). Cytokine storms may be associated with the dangerousness of the disease (Hojyo 314 et al., 2020). In a series of situations that affect the kidneys as well as the heart, 315 dysfunction of one organ can encourage dysfunction of the other organ. Chronic or acute 316 systemic conditions can impair the function of these two organs (Damman and Testani 317 2015). COVID-19-induced acute kidney injury may be related to the crosstalk between 318 the cardiovascular system and the kidney. COVID-19 set off myocarditis to weaken the 319 cardiac output and affect end-organ perfusion. Additionally, the associated proper 320 ventricular disorder produces diastolic disorder and venous congestion that transmit back 321

to the kidney and in addition compromise its blood supply via way of means of growing kidney congestion (**Legrand** *et al.*, **2021**). In addition, acute viral myocarditis together with cytokine cardiomyopathy can induce hypotension, renal venous congestion, and decreased renal blood flow, which can decrease the glomerular filtration rate (**Faour** *et al.*, **2022**).

## 327 **Conclusions**

Our study concluded that impaired renal biomarkers and cardiac enzymes may be attributed to increased expression levels of TLR2, TLR4, ACE2, and NRP-1 mRNA in both severe and moderate COVID-19 patients. So. it is critical to recognize the molecular mechanisms and focus on the vital molecules involved in the pathogenicity of the diseases to design novel drugs to control and prevent the disease. By blocking the virus access pathways including the viral receptors and regulating immune responses we can reduce multi-organ dysfunction induced by COVID-19.

335

## **Supporting information**

Fig 1 :( A, B) shows a comparison between the relative expression of TLR-2 and TLR-4 in all studied groups. There were significant (p=0.000), (p=0.000) increases respectively, in TLR2, TLR4 expression levels in moderate and severe cases compared to healthy controls.

Fig 1: (A) TLR2; Toll-like receptor 2 and (B) TLR4; Toll-like receptor 2 in moderate and severe groups compared to healthy controls.

**Fig 2:** (**C**, **D**) shows a comparison between the relative ACE2 and NRP-1 mRNA expression levels. This figure exhibited that ACE2 and NRP-1 mRNA expression levels were significantly (p=0.000, p=0.000 respectively), increased in the moderate group and severe group compared to the healthy controls group.

**Fig 2:** (C) ACE2; Angiotensin-converting enzyme- 2 and (D) NPR-1; Neuropilin-1 in

348 moderate and severe groups compared to healthy control

Fig 3: (E-I) in the moderate group, shows a significant positive correlation between urea and TLR2 (p=0.000). Also, positively correlated between CKMB and Troponin I with both TLR2 (p=0.000), (p<0.05) and TLR4 (p=0.000, p=0.000, respectively).

with both TLR2 (p=0.000), (p<0.05) and TLR4 (p=0.000, p=0.000, respectively).

**Fig 3: (E-I)** Correlations among the moderate group, between TLR2 with (E) urea, (F)

353 CKMB, (G) Troponin I and TLR4 with (H) CKMB, (I) Troponin I. Correlation was

- 354 significant \*\* at the 0.01 level, \*\*\* at the 0.001 level. CKMB: creatinine kinase
- myocardial band; TLR2, 4: Toll-like receptor 2, 4.
- **Fig4: (J-M)** ACE2 and NRP-1 mRNA expression levels, exhibited a significant positive

(p=0.000) correlation with TLR2, TLR4 in the moderate group.

**358 Fig 4: (J-M)** Correlations among the moderate group, between ACE2 with (J) TLR2, (K) **359 TLR4**, and NRP-1 with (L) TLR2, (M) TLR4. The correlation was significant \*\* at the 0.01 **360 level**, \*\*\* at the 0.001 level. ACE2: Angiotensin-converting enzyme; NPR1: Neuroplini-1 **361 and TLR2**, 4: Toll-like receptor 2, 4.

- Fig 5 :( N-Q) in the severe group, both serum creatinine and urea were positively correlated to TLR2 and TLR4 (p<0.05).
- **Fig 5: (N-Q)** Correlations among the severe group, between creatinine with (N)
- TLR2, (O) TLR4, and urea with (P) TLR2, (Q) TLR4. The correlation was significant
- <sup>366</sup> \*\* at the 0.01 level, \*\*\* at the 0.001 level. TLR2, 4: Toll-like receptor 2, 4.
- Fig 6 :( R-T) CKMB showed a positive correlation with TLR2 (p=0.000) and TLR4 (p<0.05). Furthermore, Troponin I observed a positive correlation with TLR4 (p<0.05) among the severe group.
- **Fig 6: (R-T)** Correlations among the severe group, between CKMB with (R) TLR2, (S)
- TLR4 and Troponin I with (T) TLR4. The correlation was significant \*\* at the 0.01
- level, \*\*\* at the 0.001 level. CKMB: creatinine kinase myocardial band; TLR2, 4: Toll-
- like receptor 2, 4.
- Fig 7 :( U, V) shows that ACE2 mRNA expressions were positively (p=0.000) correlated

- with TLR2 and TLR4 in the severe group.
- Fig 7: (U, V) Correlations among the severe group, between ACE2 with (U) TLR2,
- (V) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001 level.
- ACE2: Angiotensin-converting enzyme; TLR2, 4: Toll-like receptor 2, 4.
- **Fig 8: (W, X)** shows that NRP-1 mRNA expressions were positively (p=0.000)
- 381 correlated
- to TLR2 and TLR4 in the severe group.
- **Fig 8: (W, X)** Correlations among the severe group, between NRP-1 with (W) TLR2,
- (X) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001 level.
- ACE2: Angiotensin-converting enzyme; NPR-1: Neuroplini-1; TLR2, 4: Toll-like
- see receptor 2, 4.

## 387 Acknowledgments

The authors would like to thank Taif University, Taif, Saudi Arabia for supporting this research (Taif University researchers supporting project number: TURSP-2020/127). Thank you very much Dr. Ahmed Abdelhafeiz consultant of Medical Biochemistry - Al Azhar University.

392

## 393 Funding

"This work was supported by [Taif University, Taif, Saudi Arabia] (Grant number
 [TURSP-2020/127]. The author, Basem Hassan Elesawy has received research support
 from Taif University, Taif, Saudi Arabia."

397

#### **Ethics Statement**

399 The studies were reviewed and approved by the Ethics Committee of Faculty of Post-

400 graduate studies for Advanced Science, Beni-Suef University, Egypt, and approval

401 from Misr International Hospital was obtained.

#### 402 **Consent to participate**

All patients/participants or their relatives provided their written informed consent to participate in this study.

#### 405 **Authors contribution**

Conceptualization: [Maged Abdallah, Osama M. Ahmed]; Methodology: [Rabab 406 Hussain Sultan, Amr E. Ahmed, Basem Hassan Elesawy, Maged Abdallah]; Formal 407 analysis and investigation: [Hebatallah Hany Assal, Tarek Mohamed Ali, Osama M. 408 Ahmed]; Writing - original draft preparation: [Rabab Hussain Sultan, Tarek Mohamed 409 Ali, Osama M. Ahmed]; Writing - review and editing: [Tarek Mohamed Ali, Osama M. 410 Ahmed, Hebatallah Hany Assal]; Funding acquisition: [Basem Hassan Elesawy]; 411 Resources: [Rabab Hussain Sultan, Maged Abdallah, Tarek Mohamed Ali, Hebatallah 412 413 Hany Assal, Amr E. Ahmed, Basem Hassan Elesawy]; Supervision: [Osama M. Ahmed, Maged Abdallah, Hebatallah Hany Assal, Amr E. Ahmed]. 414

#### 415 **Competing Interests**

416 "The authors have no relevant financial or non-financial interests to disclose."

#### 417 **Consent to publish**

- All authors agreed with the content and that all gave explicit consent to submit and that
- they obtained consent from the responsible authorities at the institute/organization where
- 420 the work has been carried out **before** the work is submitted.

#### 421 **Data and availability of material**

- 422 All authors guarantee transparency on the re-use of material and that there is no
- 423 unpublished material (for example manuscripts in press) included in the manuscript

#### 424 **References**

Ahmadian, E.; Hosseinivan Khatibi, S. M.; Razi Soofivani, S.; Abediazar, S.; 425 Shoja, M. M.; Ardalan, M. and Zununi Vahed, S. (2021): COVID-19and kidney 426 Pathophysiology and molecular mechanisms. Reviews medical 427 injury: in virology, 31(3), e2176. 428 Basu-Ray, I.; Almaddah, N. K.; Adeboye, A. and Soos, M. P. (2021): Cardiac 429 Manifestations Of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing. 430 Blanco-Melo, D.; Nilsson-Payant, B. E.; Liu, W. C.; Uhl, S.; Hoagland, D.; Møller, 431 R.; Jordan, T. X.; Oishi, K.; Panis, M.; Sachs, D.; Wang, T. T.; Schwartz, R. E.; 432 Lim, J. K.; Albrecht, R. A., and tenOever, B. R. (2020): Imbalanced Host Response 433 to SARS-CoV-2 Drives Development of COVID-19. Cell, 181(5), 1036–1045.e9. 434 Boozari, M.; Butler, A.E. and Sahebkar A. (2019): Impact of curcumin on toll-like 435 receptors. J Cell Physiol. 2019; 234(8):12471-12482. 436 Browne E. P. (2020): The Role of Toll-Like Receptors in Retroviral 437 Infection. *Microorganisms*, 8(11), 1787. 438 Bugert, C. L.; Kwiat, V.; Valera, I. C.; Bugert, J. J. and Parvativar, M. S. (2021): 439 Cardiovascular Injury Due to SARS-CoV-2. Current clinical microbiology reports, 1-440 11. Advance online publication. 441 Buhl, S. N. and Jackson, K. Y. (1978): Optimal conditions and comparison of lactate 442 dehydrogenase catalysis of the lactate-to-pyruvate and Pyruvate-to-lactate in human 443 serum at 25, 30- and 37-degree C. Clin. Chem., 24: 828. 444 Buonaguro, F. M.; Ascierto, P. A.; Morse, G. D.; Buonaguro, L.; Puzanov, I.; 445 Tornesello, M. L.; Bréchot, C.and Gallo, R. C. (2020). Covid-19: Time for a 446 paradigm change. *Reviews in medical virology*, 30(5), e2134. 447 Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L. D.; Djannatian, M.; Franz, J.; 448 Kuivanen, S.; van der Meer, F.; Kallio, K.; Kaya, T.; Anastasina, M.; Smura, T.; 449 Levanov, L.; Szirovicza, L.; Tobi, A.; Kallio-Kokko, H.; Österlund, P.; Joensuu, 450 M.; Meunier, F. A.; Butcher, S. J.; Winkler, M. S. and Simons, M. (2020): 451 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science (New York, 452 N.Y.), 370(6518), 856-860. 453

454 Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.;

Chen, H.; Yu, H.; Zhang, X.; Zhang, M.; Wu, S.; Song, J.; Chen, T.; Han, M.; Li,

456 **S.; Luo, X.; Zhao, J. and Ning, Q. (2020):** Clinical and immunological features of 457 severe and moderate coronavirus disease 2019. *The Journal of clinical* 458 *investigation*, 130(5), 2620–2629.

- 459 Cheng, Y.; Luo, R.; Wang, K.; Zhang, M.; Wang, Z.; Dong, L.; Li, J.; Yao, Y.;
- 460 Ge, S. and Xu, G. (2020): kidney disease is associated with in-hospital death of
- 461 patients with COVID-19. *Kidney International*, 97(5), 829–838.
- 462 Choudhury, A. and Mukherjee, S. (2020): In silico studies on the comparative
  463 characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE2
  464 receptor homologs and human TLRs. *Journal of medical virology*, 92(10), 2105–2113.
- Daly, J. L.; Simonetti, B.; Klein, K.; Chen, K. E.; Williamson, M. K.; AntónPlágaro, C.; Shoemark, D. K.; Simón-Gracia, L.; Bauer, M.; Hollandi, R.; Greber,
  U. F.; Horvath, P.; Sessions, R. B.; Helenius, A.; Hiscox, J. A.; Teesalu, T.;
  Matthews, D. A.; Davidson, A. D.; Collins, B. M.; Cullen, P. J.and ... Yamauchi,
  Y. (2020): Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science (New
  York, N.Y.), 370(6518), 861–865.
- 471 Damman, K. and Testani, J. M. (2015): The kidney in heart failure: an
  472 update. *European heart journal*, *36*(23), 1437–1444.
- Fan, C.; Lu, W.; Li, K.; Ding, Y. and Wang, J. (2021): ACE2 Expression in Kidney
  and Testis May Cause Kidney and Testis Infection in COVID-19Patients. *Frontiers in medicine*, 7, 563893.
- Faour, W. H.; Choaib, A.; Issa, E., Choueiry, F. E.; Shbaklo, K.; Alhajj, M.;
  Sawaya, R. T.; Harhous, Z.; Alefishat, E. and Nader, M. (2022): Mechanisms of
  COVID-19-induced kidney injury and current pharmacotherapies. *Inflammation research: official journal of the European Histamine Research Society ... [et*al.], 71(1), 39–56.
- Freeman, T. L., and Swartz, T. H. (2020): Targeting the NLRP3 Inflammasome in
  Severe COVID-19. Frontiers in immunology, 11, 1518.
- Gheblawi, M.; Wang, K.; Viveiros, A.; Nguyen, Q.; Zhong, J. C.; Turner, A. J.;
  Raizada, M. K.; Grant, M. B. and Oudit, G. Y. (2020): Angiotensin-Converting

- Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System:
  Celebrating the 20th Anniversary of the Discovery of ACE2. *Circulation Research*, *126*(10), 1456–1474.
- Henry T.J. 2nd ed. Harper and Row Publishers (1974): New York: Clinical
  Chemistry Principles and techniques.[Google Scholar]
- Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.;
  Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N. H.; Nitsche, A.; Müller, M. A.;
  Drosten, C. and Pöhlmann, S. (2020): SARS-CoV-2 Cell Entry Depends on ACE2
  and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 181(2),
  271–280.e8.
- Hojyo, S.; Uchida, M.; Tanaka, K.; Hasebe, R.; Tanaka, Y.; Murakami, M. and
  Hirano, T. (2020): How COVID-19induces cytokine storm with high
  mortality. *Inflammation and regeneration*, 40, 37.
- 498 Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.;
- Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X..; Yin, W.; Li, H.; Liu,
  M.; Xiao, Y.and... Cao, B. (2020): Clinical features of patients infected with 2019
- novel coronavirus in Wuhan, China. *Lancet (London, England)*, *395*(10223), 497–506.
- Huang, Y.; Yang, C.; Xu, X. F.; Xu, W. and Liu, S. W. (2020): Structural and
  functional properties of SARS-CoV-2 spike protein: potential antivirus drug
  development for COVID-19. *Acta pharmacologica Sinica*, 41(9), 1141–1149.
- Imig, J. D., and Ryan, M. J. (2013): Immune and inflammatory role in renal
  disease. *Comprehensive Physiology*, 3(2), 957–976.
- index in coronavirus (COVID-19) infected patients. *British journal of haematology*, 189(3), 428–437.
- 509 Issa, H.; Eid, A. H.; Berry, B.; Takhviji, V.; Khosravi, A.; Mantash, S.; Nehme,
- 510 R.; Hallal, R.' Karaki, H.; Dhayni, K.; Faour, W. H.; Kobeissy, F.; Nehme, A. and
- 511 Zibara, K. (2021): Combination of Angiotensin (1-7) Agonists and Convalescent
- <sup>512</sup> Plasma as a New Strategy to Overcome Angiotensin-Converting Enzyme 2 (ACE2)
- 513 Inhibition for the Treatment of COVID-19. *Frontiers in medicine*, *8*, 620990.

- 514 **Kaplan A. (1984):** Urea Clin Chem. Pbl. The C.V. Mosby Co. St Louis. Toronto. 515 Princeton, PP. 1257-1260 and 437 and 418.
- Legrand, M.; Bell, S.; Forni, L.; Joannidis, M.; Koyner, J. L.; Liu, K. and Cantaluppi, V. (2021): Pathophysiology of COVID-19-associated acute kidney
- 518 injury. *Nature reviews. Nephrology*, *17*(11), 751–764.
- Li, Y.; Zhou, W.; Yang, L.; You, R. (2020): Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. *Pharmacological Research*, *157*, 104833.
- Livak, K.J. and Schmittgen, T.D. (2001): Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001; 25(4): 402–408.
- 525 **Mukherjee, S.; Karmakar, S. and Babu, S. P. (2016):** TLR2 and TLR4 mediated 526 host immune responses in major infectious diseases: a review. *The Brazilian journal of*
- 527 infectious diseases: an official publication of the Brazilian Society of Infectious
- 528 *Diseases*, 20(2), 193–204.
- 529 Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C.,
- 530 Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., Braga, L.,
- <sup>531</sup> Williamson, M. K., Hassard, J. A., Staller, E., Hanley, B., Osborn, M., Giacca, M.,
- 532 Davidson, A. D., Matthews, D. A., & Barclay, W. S. (2021). The furin cleavage site
- 533 in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nature*
- *microbiology*, *6*(7), 899–909.
- Qian, J. Y.; Wang, B.; Lv, L. L. and Liu, B. C. (2021): Pathogenesis of Acute
  Kidney Injury in Coronavirus Disease 2019. *Frontiers in physiology*, *12*, 586589.
  https://doi.org/10.3389/fphys.2021.586589.
- Raoult, D.; Zumla, A.; Locatelli, F.; Ippolito, G. and Kroemer, G.
  (2020): Coronavirus infections: epidemiological, clinical and immunological features
  and hypotheses. *Cell Stress.* 2020; 4:66-75. 10.15698/cst2020.04.216
- 541 Rivero, A.; Mora, C.; Muros, M.; García, J.; Herrera, H. and Navarro-González,
- **J. F. (2009):** Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clinical science (London, England: 1979), 116 (6), 479–492.

- Rothan, H.A., and Byrareddy, S.N. (2020): The epidemiology and pathogenesis of
  coronavirus disease (COVID-19) outbreak. *J Autoimmun*. 2020;109:102433
  10.1016/j.jaut.2020.102433
- 547 Sette, A., and Crotty, S. (2021): Adaptive immunity to SARS-CoV-2 and COVID548 19. *Cell*, 184(4), 861–880.
- Shah, V. K.; Firmal innate immune responses, P.; Alam, A.; Ganguly, D. and
  Chattopadhyay, S. (2020): Overview of Immune Response During SARS-CoV-2
  Infection: Lessons From the Past. *Frontiers in immunology*, *11*, 1949.
- Tang, Y.; Liu, J.; Zhang, D.; Xu, Z.; Ji, J. and Wen, C. (2020): Cytokine Storm in
  COVID-19: The Current Evidence and Treatment Strategies. *Frontiers in immunology*, 11, 1708.
- V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., and Thiel, V. (2021): Coronavirus
  biology and replication: implications for SARS-CoV-2. *Nature reviews*. *Microbiology*, 19(3), 155–170.
- <sup>558</sup> Wan, S.; Yi, Q.; Fan, S.; Lv, J.; Zhang, X.; Guo, L.; Lang, C.; Xiao, Q.; Xiao, K.;
- Yi, Z.; Qiang, M.; Xiang, J.; Zhang, B.; Chen, Y. and Gao, C. (2020): Relationships
  among lymphocyte subsets, cytokines, and the pulmonary inflammation
- <sup>561</sup> Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.;
- 562 Cheng, Z.; Xiong, Y, Zhao, Y.; Li, Y.; Wang, X. and Peng, Z. (2020): Clinical
- 563 Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected
- <sup>564</sup> Pneumonia in Wuhan, China. JAMA. 2020 Mar 17; 323(11):1061-1069.
- Weiss, S.R. and Navas-Martin S. (2005): Coronavirus pathogenesis and the emerging
  pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol
  Rev. 2005 Dec; 69(4):635-64.
- 568 World Health Organization, (2021): WHO Coronavirus (COVID-19) Dashboard.
- Ye, Q.; Wang, B. and Mao, J. (2020): The pathogenesis and treatment of the Cytokine Storm' in COVID-19. *The Journal of infection*, 80(6), 607–613.
- <sup>571</sup> Zhang, J. J.; Dong, X.; Cao, Y. Y.; Yuan, Y. D.; Yang, Y. B.; Yan, Y. Q.; Akdis, C.
- **A.and Gao, Y. D. (2020):** Clinical characteristics of 140 patients infected with SARS-
- 573 CoV-2 in Wuhan, China. *Allergy*, *75*(7), 1730–1741.

- <sup>574</sup> Ziegler, C.; Allon, S. J.; Nyquist, S. K.; Mbano, I. M.; Miao, V. N.; Tzouanas, C.
- 575 N.; Cao, Y.; Yousif, A. S.; Bals, J.; Hauser, B. M.; Feldman, J.; Muus, C.;
- 576 Wadsworth, M. H.; 2nd, Kazer, S. W.; Hughes, T. K.; Doran, B.; Gatter, G. J.;
- 577 Vukovic, M.; Taliaferro, F.; Mead, B. E.and ... HCA Lung Biological Network
- 578 (2020): SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human
- 579 Airway Epithelial Cells and Is Detected in Specific Cell Subsets across
- 580 Tissues. *Cell*, 181(5), 1016–1035.e19.

1

# Correlations between kidney and heart function bioindicators and the expressions of Toll-Like, ACE2, and NRP-1 receptors in COVID-19

- 4
- Rabab Hussain Sultan<sup>1\*</sup>, Maged Abdallah<sup>2</sup>, Tarek Mohamed Ali<sup>3</sup>, Hebatallah Hany
  Assal<sup>4</sup>, Amr E. Ahmed<sup>1</sup>, Basem H Elesawy<sup>5</sup>, and Osama M. Ahmed<sup>6</sup>
- 7

8 1 Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for

9 Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt.

- 2 Department of anesthesia and intensive care, Kasr Alaini hospital, Cairo University,
   Egypt.
- 12 3 Department of Physiology, College of Medicine, Taif University, P.O. Box 11099,
- 13 Taif 21944, Saudi Arabia.
- 14 4 Chest Department, Kasr Alaini hospital, Cairo University, Egypt.
- <sup>15</sup> 5 Department of Pathology, College of Medicine, Taif University, P.O. Box 11099, Taif
- 16 21944, Saudi Arabia.
- 17 6 Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef
- 18 University, P.O. Box 62521, Beni-Suef, Egypt.
- 19
- 20 Corresponding author: Rabab Hussain Sultan, 00201029819222, E-mail:
- 21 <u>rababsoltan080@gmail.com</u>
- 22
- 23
- 23
- 24
- 25
- 26
- 27
- 21
- 28
- 29

**Fig 1 :** (**A**, **B**) shows a comparison between the relative expression of TLR-2 and TLR-4

in all studied groups. There were significant (p=0.000), (p=0.000) increases respectively,

in TLR2, TLR4 expression levels in moderate and severe cases compared to healthy controls.





41

Fig 1: (A) TLR2; Toll-like receptor 2 and (B) TLR4; Toll-like receptor 2 in moderate and severe groups compared to healthy controls.

**Fig 2: (C, D)** shows a comparison between the relative ACE2 and NRP-1 mRNA expression levels. This figure exhibited that ACE2 and NRP-1 mRNA expression levels were significantly (p=0.000, p=0.000 respectively), increased in the moderate group and severe group compared to the healthy controls group.





Fig 3: (E-I) in the moderate group, shows a significant positive correlation between 44 urea and TLR2 (p=0.000). Also, positively correlated between CKMB and Troponin I 45 with both TLR2 (p=0.000), (p<0.05) and TLR4 (p=0.000, p=0.000, respectively). 46

(G)

3

2

r = 0.337

p=0.000

5

4





49

50

Fig 3: (E-I) Correlations among the moderate group, between TLR2 with (E) urea, (F) CKMB, (G) 51 Troponin I and TLR4 with (H) CKMB, (I) Troponin I. Correlation was significant \*\* at the 0.01 level, 52 \*\*\* at the 0.001 level. CKMB: creatinine kinase myocardial band; TLR2, 4: Toll-like receptor 2, 4. 53

54

55

**Fig4: (J-M)** ACE2 and NRP-1 mRNA expression levels, exhibited a significant positive (p=0.000) correlation with TLR2, TLR4 in the moderate group.



**Fig 4: (J-M)** Correlations among the moderate group, between ACE2 with (J) TLR2, (K) TLR4, and 62 NRP-1 with (L) TLR2, (M) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001 63 level. ACE2: Angiotensin-converting enzyme; NPR1: Neuroplini-1 and TLR2, 4: Toll-like receptor 2, 4.

Fig 5 :( N-Q) in the severe group, both serum creatinine and urea were positively correlated to TLR2 and TLR4 (p<0.05).



Fig 5: (N-Q) Correlations among the severe group, between creatinine with (N) TLR2, (O)
TLR4, and urea with (P) TLR2, (Q) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\*
at the 0.001 level. TLR2, 4: Toll-like receptor 2, 4.

**Fig 6 :( R-T)** CKMB showed a positive correlation with TLR2 (p=0.000) and TLR4 (p<0.05). Furthermore, Troponin I observed a positive correlation with TLR4 (p<0.05)

- 82 among the severe group.
- 83





Fig 6: (R-T) Correlations among the severe group, between CKMB with (R) TLR2, (S) TLR4 and
Troponin I with (T) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001
level.

88 CKMB: creatinine kinase myocardial band; TLR2, 4: Toll-like receptor 2, 4.

- 89
- **Fig 7 :**(**U**, **V**) shows that ACE2 mRNA expressions were positively (p=0.000) correlated
- 91 with TLR2 and TLR4 in the severe group.



**Fig 7: (U, V)** Correlations among the severe group, between ACE2 with (U) TLR2, (V) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001 level. ACE2: Angiotensin-converting enzyme; TLR2, 4: Toll-like receptor 2, 4.

96

Fig 8: (W, X) shows that NRP-1 mRNA expressions were positively (p=0.000) correlated

- to TLR2 and TLR4 in the severe group.



Fig 8: (W, X) Correlations among the severe group, between NRP-1 with (W) TLR2, (X) TLR4. The correlation was significant \*\* at the 0.01 level, \*\*\* at the 0.001 level. ACE2: Angiotensin-converting 

enzyme; NPR-1: Neuroplini-1; TLR2, 4: Toll-like receptor 2, 4.